Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New DNA testing scheme for one of Britain's rarest dogs
Otterhound breed numbers are very low.

Scheme tests for Glanzmann’s thrombasthenia in the otterhound.

A new DNA testing scheme for one of the UK's rarest dog breeds has been approved by the Kennel Club.

The official scheme tests for Glanzmann’s thrombasthenia (GT) in the otterhound - a breed which saw a mere 44 puppy registrations in 2019, and is listed by the Kennel Club as a 'Vulnerable British Breed'.

It is hoped the test will combat inherited disease in otterhounds by enabling breeders to make more informed choices when deciding to breed a litter.

Breed health coordinator, Judith Ashworth, said: “The otterhound is basically a very healthy breed. However, as their numbers are very low, breeders need every assistance they can get when it comes to ensuring the breed is preserved for future generations, partly through breeding interaction across the world.”

GT is an inherited blood-clotting disorder characterised in dogs by bruising, frequent bleeding from the nose and blood in the urine and/or stools. Dogs with the condition normally show signs before the age of one, often by bleeding from the gums as their adult teeth emerge.

To acquire the condition, a dog must inherit two copies of an abnormal gene, one from its mother and one from its father, before its health is affected. A dog that inherits one copy of an abnormal gene will have no signs of the disease, but will be a carrier and may pass the gene on to any offspring.

Dogs that undergo the Kennel Club's GT test will be classed as either:

Clear
The dog does not have any copies of the abnormal gene associated with GT. The dog is highly unlikely to be clinically affected and will pass on only a normal copy of the gene to a puppy.

Carrier
The dog has one copy of the normal gene and one copy of the abnormal gene associated with GT. The dog is unlikely to be clinically affected but may pass on one copy of the normal gene, or one copy of the abnormal gene, to a puppy.

Affected
The dog has two copies of the abnormal gene associated with GT. The dog will be clinically affected by the disorder and will pass on one copy of the abnormal gene to any potential offspring.

Test results will be added to the dog’s registration details which will trigger the publication of the result in the next available Breed Records Supplement. The result will appear on any new registration certificate issued for the dog and on the registration certificates of any future progeny of the dog, and also on the Health Test Results Finder on the Kennel Club website.

To find out which laboratories the Kennel Club can record results from, and which labs will send results direct to the Kennel Club, please refer to the worldwide DNA testing list at thekennelclub.org.uk

Image (C) Kennel Club.

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.